Neuregulin 3 is associated with attention deficits in schizophrenia and bipolar disorder

Sandra Meier, Jana Strohmaier, Rene Breuer, Manuel Mattheisen, Franziska Degenhardt, Thomas W. Mühleisen, Thomas G. Schulze, Markus M. Nöthen, Sven Cichon, Marcella Rietschel, Stefan Wüst

Research output: Contribution to journalArticle

Abstract

Linkage and fine mapping studies have established that the neuregulin 3 gene (NRG3) is a susceptibility locus for schizophrenia. Association studies of this disorder have implicated NRG3 variants in both psychotic symptoms and attention performance. Psychotic symptoms and cognitive deficits are also frequent features of bipolar disorder. The aims of the present study were to extend analysis of the association between NRG3 and psychotic symptoms and attention in schizophrenia and to determine whether these associations also apply to bipolar disorder. A total of 358 patients with schizophrenia and 111 patients with bipolar disorder were included. Psychotic symptoms were evaluated using the Operational Criteria Checklist for Psychotic Illness (OPCRIT) and attention performance was assessed using the Trail Making Test (TMT). Symptoms and performance scores were then tested for association with the NRG3 variant rs6584400. A significant association was found between the number of rs6584400 minor alleles and the total OPCRIT score for psychotic symptoms in patients with schizophrenia. Moreover, in both schizophrenia and bipolar disorder patients, minor allele carriers of rs6584400 outperformed homozygous major allele carriers in the TMT. The results suggest that rs6584400 is associated with psychotic symptoms and attention performance in schizophrenia. The finding of a significant association between rs6584400 and attention performance in bipolar disorder supports the hypothesis that this NRG3 variant confers genetic susceptibility to cognitive deficits in both schizophrenia and bipolar disorder.

Original languageEnglish (US)
Pages (from-to)549-556
Number of pages8
JournalInternational Journal of Neuropsychopharmacology
Volume16
Issue number3
DOIs
StatePublished - Apr 2013
Externally publishedYes

Fingerprint

Neuregulins
Bipolar Disorder
Schizophrenia
Trail Making Test
Genes
Alleles
Neurobehavioral Manifestations
Chromosome Mapping
Genetic Predisposition to Disease
Checklist

Keywords

  • Attention
  • bipolar disorder
  • cognition
  • neuregulin 3
  • psychotic symptoms
  • schizophrenia

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology
  • Psychiatry and Mental health

Cite this

Meier, S., Strohmaier, J., Breuer, R., Mattheisen, M., Degenhardt, F., Mühleisen, T. W., ... Wüst, S. (2013). Neuregulin 3 is associated with attention deficits in schizophrenia and bipolar disorder. International Journal of Neuropsychopharmacology, 16(3), 549-556. https://doi.org/10.1017/S1461145712000697

Neuregulin 3 is associated with attention deficits in schizophrenia and bipolar disorder. / Meier, Sandra; Strohmaier, Jana; Breuer, Rene; Mattheisen, Manuel; Degenhardt, Franziska; Mühleisen, Thomas W.; Schulze, Thomas G.; Nöthen, Markus M.; Cichon, Sven; Rietschel, Marcella; Wüst, Stefan.

In: International Journal of Neuropsychopharmacology, Vol. 16, No. 3, 04.2013, p. 549-556.

Research output: Contribution to journalArticle

Meier, S, Strohmaier, J, Breuer, R, Mattheisen, M, Degenhardt, F, Mühleisen, TW, Schulze, TG, Nöthen, MM, Cichon, S, Rietschel, M & Wüst, S 2013, 'Neuregulin 3 is associated with attention deficits in schizophrenia and bipolar disorder', International Journal of Neuropsychopharmacology, vol. 16, no. 3, pp. 549-556. https://doi.org/10.1017/S1461145712000697
Meier, Sandra ; Strohmaier, Jana ; Breuer, Rene ; Mattheisen, Manuel ; Degenhardt, Franziska ; Mühleisen, Thomas W. ; Schulze, Thomas G. ; Nöthen, Markus M. ; Cichon, Sven ; Rietschel, Marcella ; Wüst, Stefan. / Neuregulin 3 is associated with attention deficits in schizophrenia and bipolar disorder. In: International Journal of Neuropsychopharmacology. 2013 ; Vol. 16, No. 3. pp. 549-556.
@article{835ce05e5ea74dd68a0cb379cc02f9cb,
title = "Neuregulin 3 is associated with attention deficits in schizophrenia and bipolar disorder",
abstract = "Linkage and fine mapping studies have established that the neuregulin 3 gene (NRG3) is a susceptibility locus for schizophrenia. Association studies of this disorder have implicated NRG3 variants in both psychotic symptoms and attention performance. Psychotic symptoms and cognitive deficits are also frequent features of bipolar disorder. The aims of the present study were to extend analysis of the association between NRG3 and psychotic symptoms and attention in schizophrenia and to determine whether these associations also apply to bipolar disorder. A total of 358 patients with schizophrenia and 111 patients with bipolar disorder were included. Psychotic symptoms were evaluated using the Operational Criteria Checklist for Psychotic Illness (OPCRIT) and attention performance was assessed using the Trail Making Test (TMT). Symptoms and performance scores were then tested for association with the NRG3 variant rs6584400. A significant association was found between the number of rs6584400 minor alleles and the total OPCRIT score for psychotic symptoms in patients with schizophrenia. Moreover, in both schizophrenia and bipolar disorder patients, minor allele carriers of rs6584400 outperformed homozygous major allele carriers in the TMT. The results suggest that rs6584400 is associated with psychotic symptoms and attention performance in schizophrenia. The finding of a significant association between rs6584400 and attention performance in bipolar disorder supports the hypothesis that this NRG3 variant confers genetic susceptibility to cognitive deficits in both schizophrenia and bipolar disorder.",
keywords = "Attention, bipolar disorder, cognition, neuregulin 3, psychotic symptoms, schizophrenia",
author = "Sandra Meier and Jana Strohmaier and Rene Breuer and Manuel Mattheisen and Franziska Degenhardt and M{\"u}hleisen, {Thomas W.} and Schulze, {Thomas G.} and N{\"o}then, {Markus M.} and Sven Cichon and Marcella Rietschel and Stefan W{\"u}st",
year = "2013",
month = "4",
doi = "10.1017/S1461145712000697",
language = "English (US)",
volume = "16",
pages = "549--556",
journal = "International Journal of Neuropsychopharmacology",
issn = "1461-1457",
publisher = "Cambridge University Press",
number = "3",

}

TY - JOUR

T1 - Neuregulin 3 is associated with attention deficits in schizophrenia and bipolar disorder

AU - Meier, Sandra

AU - Strohmaier, Jana

AU - Breuer, Rene

AU - Mattheisen, Manuel

AU - Degenhardt, Franziska

AU - Mühleisen, Thomas W.

AU - Schulze, Thomas G.

AU - Nöthen, Markus M.

AU - Cichon, Sven

AU - Rietschel, Marcella

AU - Wüst, Stefan

PY - 2013/4

Y1 - 2013/4

N2 - Linkage and fine mapping studies have established that the neuregulin 3 gene (NRG3) is a susceptibility locus for schizophrenia. Association studies of this disorder have implicated NRG3 variants in both psychotic symptoms and attention performance. Psychotic symptoms and cognitive deficits are also frequent features of bipolar disorder. The aims of the present study were to extend analysis of the association between NRG3 and psychotic symptoms and attention in schizophrenia and to determine whether these associations also apply to bipolar disorder. A total of 358 patients with schizophrenia and 111 patients with bipolar disorder were included. Psychotic symptoms were evaluated using the Operational Criteria Checklist for Psychotic Illness (OPCRIT) and attention performance was assessed using the Trail Making Test (TMT). Symptoms and performance scores were then tested for association with the NRG3 variant rs6584400. A significant association was found between the number of rs6584400 minor alleles and the total OPCRIT score for psychotic symptoms in patients with schizophrenia. Moreover, in both schizophrenia and bipolar disorder patients, minor allele carriers of rs6584400 outperformed homozygous major allele carriers in the TMT. The results suggest that rs6584400 is associated with psychotic symptoms and attention performance in schizophrenia. The finding of a significant association between rs6584400 and attention performance in bipolar disorder supports the hypothesis that this NRG3 variant confers genetic susceptibility to cognitive deficits in both schizophrenia and bipolar disorder.

AB - Linkage and fine mapping studies have established that the neuregulin 3 gene (NRG3) is a susceptibility locus for schizophrenia. Association studies of this disorder have implicated NRG3 variants in both psychotic symptoms and attention performance. Psychotic symptoms and cognitive deficits are also frequent features of bipolar disorder. The aims of the present study were to extend analysis of the association between NRG3 and psychotic symptoms and attention in schizophrenia and to determine whether these associations also apply to bipolar disorder. A total of 358 patients with schizophrenia and 111 patients with bipolar disorder were included. Psychotic symptoms were evaluated using the Operational Criteria Checklist for Psychotic Illness (OPCRIT) and attention performance was assessed using the Trail Making Test (TMT). Symptoms and performance scores were then tested for association with the NRG3 variant rs6584400. A significant association was found between the number of rs6584400 minor alleles and the total OPCRIT score for psychotic symptoms in patients with schizophrenia. Moreover, in both schizophrenia and bipolar disorder patients, minor allele carriers of rs6584400 outperformed homozygous major allele carriers in the TMT. The results suggest that rs6584400 is associated with psychotic symptoms and attention performance in schizophrenia. The finding of a significant association between rs6584400 and attention performance in bipolar disorder supports the hypothesis that this NRG3 variant confers genetic susceptibility to cognitive deficits in both schizophrenia and bipolar disorder.

KW - Attention

KW - bipolar disorder

KW - cognition

KW - neuregulin 3

KW - psychotic symptoms

KW - schizophrenia

UR - http://www.scopus.com/inward/record.url?scp=84874593961&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84874593961&partnerID=8YFLogxK

U2 - 10.1017/S1461145712000697

DO - 10.1017/S1461145712000697

M3 - Article

VL - 16

SP - 549

EP - 556

JO - International Journal of Neuropsychopharmacology

JF - International Journal of Neuropsychopharmacology

SN - 1461-1457

IS - 3

ER -